壳聚糖和帕米膦酸双修饰的固体脂质纳米粒的制备

目的:制备壳聚糖和帕米膦酸双修饰的固体脂质纳米粒。方法:首先利用课题组发表的专利合成帕米膦酸修饰Brij78的新型非离子表面活性剂(Pa-Brij78),然后以壳聚糖(CS)溶液为水相,Pa-Brij78为乳化剂,E-Wax为油相,采用微乳法,利用修饰的帕米膦酸基团与壳聚糖分子链中质子化的氨基交联反应原理,通过一系列实验条件的探索,确定了最佳实验工艺条件,成功制备了壳聚糖和帕米膦酸双修饰的固体脂质纳米粒。通过动态光散射(DLS)粒径仪测定了纳米粒的粒径大小和Zeta电位;透射电子显微镜(TEM)对CS-Pa-Brij78-SLNs的形貌结构进行了表征。结果:实验结果显示,制备壳聚糖和帕米膦酸双修饰的固体脂质纳米粒的最佳条件为:p H=6.0,壳聚糖浓度分别为0.1%,0.2%;反应温度65℃,反应时间40 min,在该条件下,制备的壳聚糖和帕米膦酸双修饰的固体脂质纳米粒(CS-Pa-Brij78-SLNs)粒径分别为97.9±6.6 nm和182.4±62.2 nm,表面电位分别为(+5.21±1.4m V);(+7.94±0.80 m V),装载姜黄素时,载药量为10%,包封率在90%以上,透射电镜下观察其形态圆整,清晰可见壳聚糖包裹的电晕。结论:本文以壳聚糖(CS)溶液为水相,合成的新型非离子表面活性剂Pa-Brij78为乳化剂,E-Wax为油相,采用微乳化法,经过最佳实验条件的探索,通过一步法成功制备了稳定的壳聚糖和帕米膦酸双修饰的固体脂质纳米粒(CS-Pa-Brij78-SLNs)。     

牛血红蛋白PLGA纳米粒的制备及其体外功能的研究

目的:利用poly(lactide-co-glycolide)(PLGA)和poly(styrene-co-4-styrene-sulfonate)(PSS)制备带负电荷的牛血红蛋白纳米粒,并对其载氧性能和体外性能进行评价.方法:采用溶剂蒸发法制备出空白的PLGA-PSS的空白纳米粒,通过改变pH值,吸附牛血红蛋白,从而制备出牛血红蛋白PLGA纳米粒.通过TEM、粒径、Zeta电位、包裹率和载药量、体外释放及其携氧能力对该纳米粒进行了综合分析.结果:Hb-PLGA-PSS-NPsTEM电镜下呈类球形,平均粒径为226.8±23.4nm,Zeta电位为-68.62 mV,优化条件后最大包裹率约为99.3%,载药量约为28.6%,在37℃,pH7.4的PBS溶液中释放缓慢.通过对Hb结构的分析表明此工艺未对蛋白的结构造成影响,体外携氧实验测量了P50(29mmHg)和Hill系数(2.036),结果说明该Hb纳米微囊具有良好携氧功能.结论:成功制备了一种Hb-PLGA-PSS-NPs纳米粒,稳定性好,具有很好的携氧能力.     

分枝PEI 修饰的PLGA 纳米粒转染DNA 的研究*

目的:建立基于聚(乳酸-羟基乙酸)纳米粒(PLGA)载DNA的基因转染体系,比较用空白聚(乳酸-羟基乙酸)纳米粒(PLG-A-E)吸附质粒DNA和用分枝PEI修饰后的PLGA纳米粒(PLGA-BPEI)吸附质粒DNA优缺点。方法:用乳化蒸发法制备纳米粒,对纳米粒进行表征研究,包括包封率、Zeta电位、粒径大小、稳定性,用荧光显微镜观察它们对NIH3T3和HEK293细胞的转染效率,用MTT检测对它们细胞的毒性。结果:制备了两种基于PLGA的纳米粒,PLGA-E和PLGA-BPEI粒径大小为200-270nm,zeta电位为0-30mV,在血清和不同的pH值时两者均较稳定,转染效率PLGA-BPEI较PLGA-E高,且释放时间早,但前者较后者对细胞毒性大。结论:这两种基于PLGA纳米粒均能有效转染质粒DNA,它们存在不同的优缺点,应根据不同需要进行选择。     

聚合物脂质纳米球的制备优化

目的:制备粒径均一且稳定、载药率和包埋率较高的聚合物脂质纳米球。方法:将HSPC(氢化大豆卵磷脂)与PLGA(聚乳酸-羟基乙酸共聚物)两种材料结合,利用超声复乳法制备聚合物脂质纳米球,采用响应面法优化最佳制备工艺;以HSPC(氢化大豆卵磷脂)与PLGA(聚乳酸-羟基乙酸共聚物)的比例、PVA浓度、超声功率为条件优化制备参数,以粒径为响应值。结果:优化后的最佳工艺参数为:HSPC与PLGA的比例为1:10,PVA浓度为0.66%,超声功率为51.34%(205.36 W)。结论:按最优工艺制备出的聚合物脂质纳米粒的粒径为230 nm左右,多分散系数(PDI)值为0.057,与预测值偏差较小,且粒径分布均一,可作为蛋白及多肽类药物的递送载体。     

RGD修饰包载超顺磁性氧化铁纳米粒用于脑胶质瘤的靶向研究

目的：采用PLGA-PEG为聚合材料,制备RGD修饰包载超顺磁性四氧化三铁纳米粒子（RGD-NP—Fe3O4）,用于脑胶质瘤细胞靶向核磁共振成像纳米探针。方法：采用沉淀法制备RGD修饰的栽超顺磁性纳米粒,考察纳米粒的粒径,电位等理化指标以及细胞毒性。通过细胞以及肿瘤球摄取实验,考察RGD．NP—Fe304的脑胶质瘤细胞靶向性。结果：制备得到的RGD-NP-Fe3O4粒径在85±7．5nm,电位为18＋1．15mV。纳米粒浓度在300μg/mL范围内,对脑胶质瘤细胞均无显著毒性。经过RGD修饰后脑胶质瘤细胞U87对纳米粒的摄取效率大大提高,纳米粒穿透肿瘤球能力显著增强。结论：RGD修饰包载超顺磁性氧化铁纳米粒是一种潜在的高效的脑胶质瘤细胞靶向诊断纳米探针和靶向给药系统。     

靶向肿瘤新生血管纳米粒的构建和质量控制

目的：制备F56多肽修饰的长春新碱纳米粒（F56-VCR-NP）,并建立其质量控制方法。方法：乳化－溶剂挥发法优化制备F56．VCR-NP：HPLC法测定其载药量、包封率,透射电镜下观察其形态,激光粒度分析仪测定其粒径和Zeta电位,CBQCA试剂盒测定纳米粒表面多肽密度,XPS进行表面元素分析。结果：优化制备的F56－VCR-NP粒径约为153nm,Zeta电位为－20．8mv,包封率为21．4％,载药量为1．9％,多肽连接效率为26．3％。结论：以聚乙二醇－聚乳酸（PEG-PLA）为原料,长春新碱为模型药物,成功制备出纳米粒子,并建立起有效的质量控制方法,对该实验样品进行了表征。结果表明此类纳米粒子尺寸均匀,表面多价连接F56多肽,载药量和包封率稳定可控,工艺成熟。     

pH敏感纳米粒的制备和功能表征

目的:制备具有pH响应的甲氧基聚乙二醇甲基丙烯酸-2-六亚甲基亚胺乙酯聚合物,测试材料pH功能响应,以及建立聚合物纳米粒载药方法。方法:通过核磁共振氢谱鉴定ATRP(Atom Transfer Radical Polymerization)聚合反应所获得的化合物结构。滴加-搅拌挥发法制备聚乙二醇甲基丙烯酸-2-六亚甲基亚胺乙酯纳米粒,酶标仪测定其载药量和包封率。透射电镜下观察其形态,激光粒度仪分析测定其粒径,包载DiR红外荧光探针检测纳米粒pH响应功能。结果:分别成功合成得到2-溴代异丁酸聚乙二醇单甲醚和甲基丙烯酸-2-六亚甲基亚胺乙酯单体。通过ATRP聚合反应成功合成聚乙二醇甲基丙烯酸-2-六亚甲基亚胺乙酯聚合物材料,并通过核磁氢谱对聚合材料进行鉴定。通过滴加搅拌法制备包载有模型药物香豆素-6的纳米粒,并对纳米粒的形态表征及载药量进行测定。结论:试验结果表明制备得到的聚合物纳米粒尺寸均匀,具有预期的pH响应效果,可以装载模型药物。     

包载紫杉醇PLGA纳米粒的制备工艺优化及表征

以生物可降解材料乳酸-羟基乙酸共聚物[poly(lactic-co-glycolic acid),PLGA]为载体材料,采用乳化-溶剂挥发法制备包载紫杉醇(PTX)的PLGA微球(PTX-PLGANPs)。采用正交实验设计,考察乳化剂质量浓度、PLGA与紫杉醇质量比、油相用量、剪切速度4个因素对粒径和载药率的影响,优化纳米粒最佳制备工艺。研究结果表明:当PLGA与PTX的质量比为4∶1,聚乙烯醇PVA用量0.1%,二氯甲烷用量为4mL,剪切速度为16000r·min^-1是纳米粒的最佳制备工艺。最佳工艺条件下的PTX-PLGANPs多批次重复实验得到PLGA-NPs粒径分布为(207.1±20.5)nm,Zeta电位为(-23.8±2.5)mV,载药量为(14.45±0.04)%。制得的PTX-PLGANPs均匀圆整、理化性质稳定。冻干粉复溶溶液12h粒径变化不大,具有良好的药物稳定性,为新型抗肿瘤缓释制剂的研发提供实验基础。     

基于巨噬细胞的诊疗一体化系统

目的:建立一种可以同时实现显像诊断与主动靶向到肿瘤部位进行治疗的纳米药物模型。方法:包载了1,1'-二十八烷基-3,3,3',3'-四甲基吲哚三碳花青碘(1,1'-dioctadecyl-3,3,3',3'-tetramethylindotricarbocyanine iodide, Di R)荧光染料的聚乳酸-羟基乙酸共聚物(Polylactic-co-glycolic acid, PLGA)纳米粒表面被金属离子与酚羟基络合形成的网状结构涂布后可稳定连接在巨噬细胞表面,Di R可以在近红外激光下实现荧光成像,并经波长为808 nm的近红外激光器以2 W/cm2功率照射,产生光热作用。结果:构建了粒径在100 nm左右的包载了Di R的PLGA纳米粒,表面涂布金属多酚网状结构后,纳米粒连接到巨噬细胞表面,Di R发挥既可荧光成像,经808 nm激光照射后又可高效升温至46℃以上,使用CCK8试剂检测证明此种连接了纳米粒的功能化细胞(Functional Cell)发挥光热作用后可杀死近70%的小鼠乳腺癌细胞4T1。结论:成功建立了一种基于巨噬细胞递送的诊疗一体化系统,将荧光成像与光热治疗有机结合到一起,达到有效杀伤肿瘤细胞的功效。     

蛙凝素修饰聚谷氨酸纳米粒的制备、表征及Calu-3细胞摄取研究

目的:考察蛙凝素(Odorranalectin,OL)修饰对聚谷氨酸苄酯-聚乙二醇纳米粒(PBLG-PEG-NPs)材料的Calu-3细胞(人肺腺癌细胞)毒性和细胞摄取作用的影响。方法:碘氧化法制备蛙凝素修饰聚合物材料;以姜黄素(curcumin,Cur)为模型药物,采用乳化溶媒蒸发法制备聚谷氨酸苄酯-聚乙二醇纳米粒(PBLG-PEG-NPs)和蛙凝素修饰聚谷氨酸苄酯-聚乙二醇纳米粒(OL-PBLG-PEG-NPs);MTT法考察三种纳米粒对Calu-3的细胞毒性;采用激光共聚焦显微镜对两种纳米粒的Calu-3细胞摄取作用进行定性观察。结果:给予高浓度(2 mg·mL-1)纳米粒培养Calu-3细胞时,细胞存活率大于75%。蛙凝素修饰纳米粒后其被细胞摄取的量从62.7%增加到了81.2%。结论:OL可用于黏膜给药载体的修饰,OL-PBLG-PEG-NPs细胞毒性低、生物相容性好,有望成为一种鼻腔粘膜给药优良载体。     

Formation of core/shell nanoparticles with a lipid core and their application as a drug delivery system

A novel preparation method for core/shell nanoparticles with a drug-loaded lipid core was designed and characterized. The lipid core is composed of lecithin and a drug, and the polymeric shell is composed of Pluronics (poly(ethylene oxide)-poly (propylene oxide)-poly(ethylene oxide) triblock copolymer, F-127). For the formation of stabilized core/shell nanoparticles, freeze-drying was performed in the presence of trehalose used as a cryoprotectant. Cryogenic transmittance electron microscopy (cryo-TEM), differential scanning calorimetry (DSC), and a particle size analyzer were used to observe the formation of the stabilized core/shell nanoparticles. For the application of the core/shell nanoparticles as a drug carrier, paclitaxel, a potent anticancer drug, was loaded into the core/shell nanoparticles, and the drug loading amount and the drug release pattern were observed.     

The effect of titanium with heparin/BMP-2 complex for improving osteoblast activity

The objective of this study was to investigate the enhanced osteoblast activity of MG-63 cells cultured on titanium (Ti) with a heparin/BMP-2 (Hep/BMP-2) complex. The Ti substrates were initially modified by chemical grafting poly-l-lysine (PLL) using condensing agent, followed by immobilizing the heparin/BMP-2 complex to the PLL-grafted Ti substrate via electrostatic interactions. The surface modification of Ti substrates with PLL and/or Hep/BMP-2 complex were confirmed with scanning electron microscopy, contact angle measurements, and X-ray photoelectron spectroscopy. Immobilized BMP-2 was released from the Hep/BMP-2/Ti substrate in a sustained manner. In vitro studies revealed that osteoblasts grown on Hep/BMP-2/Ti substrate increased ALP activity, calcium deposition, ALP and osteocalcin levels as compared to those grown on pristine Ti or PLL-Ti. These results indicated that heparin/BMP-2 complex immobilized Ti substrate can be useful to effectively improve osteoblast activity.     

Specific targeting of HER2 overexpressing breast cancer cells with doxorubicin-loaded trastuzumab-modified human serum albumin nanoparticles

Specific targeting of tumor cells to achieve higher drug levels in tumor tissue and to overcome cardiotoxic and other secondary effects is the major goal in cancer therapy. With trastuzumab as a humanized monoclonal antibody binding, the HER2 receptor specific targeting is possible. In the present study, target-oriented nanoparticles based on biodegradable human serum albumin (HSA) loaded with cytostatic drug doxorubicin were developed. The surface of the nanoparticles was modified by covalent attachment of trastuzumab. HER2 overexpressing breast cancer cells showed a good cellular binding and uptake of these nanoparticles. The specific transport of the cytostatic drug doxorubicin with this nanoparticulate formulation into the HER2 overexpressing breast cancer cells, their release, and biological activity was demonstrated. The results indicate that these cell-type specific drug-loaded nanoparticles could achieve an improvement in cancer therapy. To our knowledge, this is the first study demonstrating a specific trastuzumab-based targeting of HER2 overexpressing breast cancer cells with doxorubicin-loaded nanoparticles.     

Titanium Surface Priming with Phase-Transited Lysozyme to Establish a Silver Nanoparticle-Loaded Chitosan/Hyaluronic Acid Antibacterial Multilayer via Layer-by-Layer Self-Assembly

Objectives

The formation of biofilm around implants, which is induced by immediate bacterial colonization after installation, is the primary cause of post-operation infection. Initial surface modification is usually required to incorporate antibacterial agents on titanium (Ti) surfaces to inhibit biofilm formation. However, simple and effective priming methods are still lacking for the development of an initial functional layer as a base for subsequent coatings on titanium surfaces. The purpose of our work was to establish a novel initial layer on Ti surfaces using phase-transited lysozyme (PTL), on which multilayer coatings can incorporate silver nanoparticles (AgNP) using chitosan (CS) and hyaluronic acid (HA) via a layer-by-layer (LbL) self-assembly technique.

Methods

In this study, the surfaces of Ti substrates were primed by dipping into a mixture of lysozyme and tris(2-carboxyethyl)phosphine (TCEP) to obtain PTL-functionalized Ti substrates. The subsequent alternating coatings of HA and chitosan loaded with AgNP onto the precursor layer of PTL were carried out via LbL self-assembly to construct multilayer coatings on Ti substrates.

Results

The results of SEM and XPS indicated that the necklace-like PTL and self-assembled multilayer were successfully immobilized on the Ti substrates. The multilayer coatings loaded with AgNP can kill planktonic and adherent bacteria to 100% during the first 4 days. The antibacterial efficacy of the samples against planktonic and adherent bacteria achieved 65%-90% after 14 days. The sustained release of Ag over 14 days can prevent bacterial invasion until mucosa healing. Although the AgNP-containing structure showed some cytotoxicity, the toxicity can be reduced by controlling the Ag release rate and concentration.

Conclusions

The PTL priming method provides a promising strategy for fabricating long-term antibacterial multilayer coatings on titanium surfaces via the LbL self-assembly technique, which is effective in preventing implant-associated infections in the early stage.     

Microstructure analysis and wear behavior of titanium cermet femoral head with hard TiC layer

Titanium cermet was successfully synthesized and formed a thin gradient titanium carbide coating on the surface of Ti6Al4V alloy by using a novel sequential carburization under high temperature, while the titanium cermet femoral head was produced. The titanium cermet phase and surface topography were characterized with X-ray diffraction (XRD) and backscattered electron imaging (BSE). And then the wear behavior of titanium cermet femoral head was investigated by using CUMT II artificial joint hip simulator. The surface characterization indicates that carbon effectively diffused into the titanium alloys and formed a hard TiC layer on the Ti6Al4V alloys surface with a micro-porous structure. The artificial hip joint experimental results show that titanium cermet femoral head could not only improve the wear resistance of artificial femoral head, but also decrease the wear of UHMWPE joint cup. In addition, the carburized titanium alloy femoral head could effectively control the UHMWPE debris distribution, and increase the size of UHMWPE debris. All of the results suggest that titanium cermet is a prospective femoral head material in artificial joint.     

Interaction of a flavone loaded on surface-modified dextran-spooled superparamagnetic nanoparticles with β-cyclodextrin and DNA

Flavones are biologically active compounds obtained mainly from plant sources. Pharmaceutically important compounds can be delivered to the physiological target by loading them in carriers like cyclodextrins and magnetic nanoparticles. Herein, the binding of 6-methoxyflavone to β-cyclodextrin and DNA is studied using UV–visible absorption and fluorescence spectroscopy. The loading of 6-methoxyflavone onto a magnetic nanoparticles is employed. β-cyclodextrin encapsulates the 6-methoxyflavone to form an inclusion complex. β-cyclodextrin also used to draw forth 6-methoxyflavone loaded onto a magnetic nanoparticles. The morphology, magnetic property and the crystallite size of the nanoparticles are studied using scanning electron microscopy, vibrating sample magnetometry and X-ray diffraction techniques, respectively. The binding of the drug-loaded magnetic nanoparticles to DNA shows that the compound is accessible to DNA and available mostly on the surface of the nanoparticles despite a modified dextan polymer supposedly encapsulates the flavone.     

Antibody targeting of camptothecin-loaded PLGA nanoparticles to tumor cells

Antibody targeting of drug substances can improve the efficacy of the active molecule, improving distribution and concentration of the drug at the site of injury/disease. Encapsulation of drug substances into polymeric nanoparticles can also improve the therapeutic effects of such compounds by protecting the molecule until its action is required. In this current study, we have brought together these two rationales to develop a novel immuno-nanoparticle with improved therapeutic effect against colorectal tumor cells. This nanoparticle comprised a layer of peripheral antibodies (Ab) directed toward the Fas receptor (CD95/Apo-1) covalently attached to poly(lactide-co-glycolide) nanoparticles (NP) loaded with camptothecin. Variations in surface carboxyl density permitted up to 48.5 microg coupled Ab per mg of NP and analysis of nanoparticulate cores showed efficient camptothecin loading. Fluorescence visualization studies confirmed internalization of nanoconstructs into endocytic compartments of HCT116 cells, an effect not evident in NP without superficial Ab. Cytotoxicity studies were then carried out against HCT116 cells. After 72 h, camptothecin solution resulted in an IC 50 of 21.8 ng mL (-1). Ab-directed delivery of NP-encapsulated camptothecin was shown to be considerably more effective with an IC 50 of 0.37 ng mL (-1). Calculation of synergistic ratios for these nanoconstructs demonstrated synergy of pharmacological relevance. Indeed, the results in this paper suggest that the attachment of anti-Fas antibodies to camptothecin-loaded nanoparticles may result in a therapeutic strategy that could have potential in the treatment of tumors expressing death receptors.     

Does titanium in ionic form display a tissue-specific distribution?

Most studies have focused on the biodistribution of titanium(IV) oxide as nanoparticles or crystals in organism. But several reports suggested that titanium is released from implant in ionic form. Therefore, gaining insight into toxicokinetics of Ti ions will give valuable information, which may be useful when assessing the health risks of long-term exposure to titanium alloy implants in patients. A micro synchrotron radiation-induced X-ray fluorescence (µ-SRXRF) was utilized to investigate the titanium distribution in the liver, spleen and kidneys of rats following single intravenous or 30-days oral administration of metal (6 mg Ti/b.w.) in ionic form. Titanium was mainly retained in kidneys after both intravenous and oral dosing, and also its compartmentalization in this organ was observed. Titanium in the liver was non-uniformly distributed—metal accumulated in single aggregates, and some of them were also enriched in calcium. Correlation analysis showed that metal did not displace essential elements, and in liver titanium strongly correlated with calcium. Two-dimensional maps of Ti distribution show that the location of the element is characteristic for the route of administration and time of exposure. We demonstrated that µ-SRXRF can provide information on the distribution of titanium in internal structures of whole organs, which helps in enhancing our understanding of the mechanism of ionic titanium accumulation in the body. This is significant due to the popularity of titanium implants and the potential release of metal ions from them to the organism.     

Causative factors behind poloxamer 188 (Pluronic F68, Flocor)-induced complement activation in human sera. A protective role against poloxamer-mediated complement activation by elevated serum lipoprotein levels

Poloxamer 188 is a complex polydisperse mixture of non-ionic macromolecules. Adverse non-IgE-mediated hypersensitivity reactions occur in some individuals following intravenous injection of poloxamer 188-based pharmaceuticals, presumably via complement activation. Here we have delineated potential causal chemical and biological interactive factors behind poloxamer 188-induced complement activation in human serum specimens. We identified the molecular constituents inherent in poloxamer 188 preparations and studied their effect on generation of the two complement split products, SC5b-9 and Bb. Poloxamer 188 activated complement at sub-micellar concentrations and the results indicated the potential involvement of all three known complement activation pathways. The poloxamer-induced rise of SC5b-9 in human sera was abolished in the presence of a recombinant truncated soluble form of complement receptor type 1, thus confirming the role of C3/C5 convertases in the activation process. Poloxamer 188-mediated complement activation is an intrinsic property of these macromolecules and was independent of the degree of sample polydispersity, as opposed to other non-polymeric constituents. Poloxamer 188 preparations also contained unsaturated chains of diblock copolymers capable of generating SC5b-9 in human sera; this effect was terminated following the removal of double bonds by catalytic hydrogenation. By quasi-elastic light scattering, we established interaction between poloxamer and lipoproteins; interestingly, poloxamer-induced rise in SC5b-9 was significantly suppressed when serum HDL and LDL cholesterol levels were increased above normal to mimic two relevant clinical situations. This observation was consistent with previously reported data from patients with abnormal or elevated lipid profiles where no or poor complement activation by poloxamer 188 occurred. Our findings could provide the basis of novel approaches to the prevention of poloxamer-mediated complement activation.